Scarica l'app Stockscreener
9.45
0.32%
-0.03
Dopo l'orario di chiusura:
9.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.48
Aprire:
$9.53
Volume 24 ore:
321.67K
Relative Volume:
0.64
Capitalizzazione di mercato:
$328.35M
Reddito:
$85.23M
Utile/perdita netta:
$2.70M
Rapporto P/E:
150.48
EPS:
0.0628
Flusso di cassa netto:
$20.97M
1 W Prestazione:
+4.07%
1M Prestazione:
+1.50%
6M Prestazione:
-12.82%
1 anno Prestazione:
-21.77%
Intervallo 1D:
$9.32
$9.77
Intervallo di 1 settimana:
$8.84
$9.77
Portata 52W:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Nome
Delcath Systems Inc
Settore
Industria
Telefono
(518) 743-8892
Indirizzo
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
9.45 | 328.35M | 85.23M | 2.70M | 20.97M | 0.0628 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-28 | Iniziato | Craig Hallum | Buy |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2022-07-26 | Ripresa | Canaccord Genuity | Buy |
| 2021-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Canaccord Genuity | Buy |
| 2021-01-05 | Iniziato | BTIG Research | Buy |
| 2020-06-01 | Iniziato | Laidlaw | Buy |
Mostra tutto
Delcath Systems Inc Borsa (DCTH) Ultime notizie
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com
DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Craig-Hallum cuts Delcath Systems stock price target on revenue guide - Investing.com Canada
BTIG lowers Delcath Systems stock price target to $19 on guidance - Investing.com Australia
Delcath Systems (DCTH) First Profitable Year Tests Lofty 115.7x P/E Narrative - simplywall.st
BTIG Maintains Buy on Delcath Systems (DCTH) Feb 2026, PT Cut to $19 - Meyka
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Rec - GuruFocus
Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers - MSN
Delcath Systems Q4 Earnings Call Highlights - MarketBeat
Earnings Call Summary | Delcath Systems(DCTH.US) Q4 2025 Earnings Conference - 富途牛牛
DCTH: BTIG Lowers Price Target, Maintains Buy Rating for Delcath Systems | DCTH Stock News - GuruFocus
BTIG Research Cuts Delcath Systems (NASDAQ:DCTH) Price Target to $19.00 - MarketBeat
Earnings call transcript: Delcath Systems Q4 2025 sees revenue beat, stock dips - Investing.com Nigeria
Clear Street lowers Delcath Systems stock price target on revised revenue outlook - Investing.com Canada
Delcath Systems Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck - Barchart.com
Delcath (DCTH) Reports Strong Q4 Revenue and Anticipates Future Growth - GuruFocus
DCTH Forecasts Robust Gross Margin for Fiscal Year 2026 - GuruFocus
DCTH: Record revenue, strong growth, and CHOPIN data set stage for further expansion in 2026 - TradingView
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results - BioSpace
DELCATH SYSTEMS, INC. SEC 10-K Report - TradingView
DELCATH SYSTEMS ($DCTH) Releases Q4 2025 Earnings - Quiver Quantitative
Delcath Systems Inc Azioni (DCTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):